Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

PURPOSE: In patients with unresectable stage III non-small-cell lung cancer (NSCLC), durvalumab maintenance treatment after chemoradiotherapy (CRT) significantly improves survival. So far, however, metabolic changes of tumoral lesions and secondary lymphoid organs under durvalumab are unknown. Hence...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzgreve, Adrien, Taugner, Julian, Käsmann, Lukas, Müller, Philipp, Tufman, Amanda, Reinmuth, Niels, Li, Minglun, Winkelmann, Michael, Unterrainer, Lena M., Nieto, Alexander E., Bartenstein, Peter, Kunz, Wolfgang G., Ricke, Jens, Belka, Claus, Eze, Chukwuka, Unterrainer, Marcus, Manapov, Farkhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250493/
https://www.ncbi.nlm.nih.gov/pubmed/36951991
http://dx.doi.org/10.1007/s00259-023-06192-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250493/
https://www.ncbi.nlm.nih.gov/pubmed/36951991
http://dx.doi.org/10.1007/s00259-023-06192-6

Ejemplares similares